New Market Report: Ghana Pharmaceuticals & Healthcare Report Q2 2014

Although our USD headline forecasts for Ghana in Q2014 have been revised lower, this is largely due to currency fluctuations. We remain positive towards Ghana's healthcare and pharmaceutical markets over the long term. This is due to the government's commitment to the National Health Insurance Scheme, which is recognised as one of the best in the region, and currently covers over 36% of the population, according to Oxfam. The government continues to enrol more people and is undertaking steps to improve efficiency. In addition, the Prime Minister's commitment to manufacturing drugs for malaria, anti-retrovirals and TB, bringing in the expertise of German Development Agency and Novartis' Sandoz, will open up possibilities for regional exports and WHO pre-qualification for local manufacturers, while simultaneously decreasing reliance on drugs imported from India.

Full Report Details at
- http://www.fastmr.com/prod/799950_ghana_pharmaceuticals_healthcare_report_q2_2014.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: GHS708mn (US$343mn) in 2013 to GHS868mn (US$356mn) in 2014; +22.5% in local currency terms and +3.9% in US dollar terms. Forecast in local currency terms revised from Q114 due to currency fluctuations.

Healthcare: GHS3.77bn (US$1.83bn) in 2013 to GHS4.28bn (US$1.75bn) in 2013; +13.4% in local currency terms and -3.9% in US dollar terms. Forecast in US dollar terms downgraded from Q114 due to local currency fluctuations.

Risk/Reward Ratings

Ghana's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 39.2, making it the 18th most attractive market in the Middle East and African region.

Key Trends And Developments

In March 2014, under a three-year development partnership with the German Development Agency, GTZ, Ghana's minister of industry and trade announced a project to produce key medicines locally. The project aims to increase human capacity development for pharmaceutical manufacturing, co-development and prequalification of key medicines against priority endemic diseases, including TB, anti-malarials and antiretrovitals.

The Ghanaian government also received support from the EU's Trade-related assurance and Quality Enabling Programme (TRAQUE) to increase the capacity of standards and regulatory bodies such as Food and Drugs Authority and the Ghana Standards Authority to ensure quality. An improvement in standards would be a positive development for patented drugs in the country.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Malaysia Pharmaceuticals & Healthcare Report Q2 2014
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Bangladesh Pharmaceuticals & Healthcare Report Q2 2014